DELFI Diagnostics Secures New York Approval for AI-Powered Lung Cancer Blood Test
PALO ALTO, California, May 28, 2026 DELFI Diagnostics has achieved a significant regulatory milestone after receiving a Clinical Laboratory...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PALO ALTO, California, May 28, 2026 DELFI Diagnostics has achieved a significant regulatory milestone after receiving a Clinical Laboratory...
PALO ALTO, Calif., May 13, 2026 DELFI Diagnostics announced that it will present the first-ever clinical utility data for...
